Cited by 1,088Cystic Fibrosis Research AdvancesIon Transport and Channel RegulationInhalation and Respiratory Drug Delivery

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Open access

Van Goor, Fredrick, Hadida, Sabine, Grootenhuis, Peter D. J., Burton, Bill, Stack, Jeffrey H., Straley, Kimberly S., Decker, Caroline J., Miller, Mark, McCartney, Jason, Olson, Eric R., Wine, Jeffrey J., Frizzell, Ray A., Ashlock, Melissa, Negulescu, Paul A.·2011·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1105787108PMC PMC3219147

Open this paper in CoChat — free account

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC 50 , 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.

Integrity signals

Registry

Crossref · 10.1073/pnas.1105787108

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225
Self-citation
Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093
Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803
Self-citation
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624
Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Show all 44 references

Research works printed but not linked: 1

; Cystic Fibrosis Foundation US Cystic Fibrosis Patient Registry (Cystic Fibrosis Foundation, Bethesda, 2002).

Sorted by citations

Items 801–900 of 1,000

The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis
Chermensky, A. G., Gembitskaya, T. E., Орлов, А. В., & Makhmutova, V. R. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-4-98-106 · Cited by 5
A Review of Treatments That Improve Cystic Fibrosis Transmembrane Conductance Regulator Function
Shanthikumar, S., & Massie, J. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719123 · Cited by 5
CFTR and Cystic Fibrosis: A Need for Personalized Medicine
Bradbury, N. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3366-2_24 · Cited by 5
Mucoviscidose : nouvelles thérapeutiques ciblant la protéine CFTR
Fajac, I., & Sermet‐Gaudelus, I. (2013) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2012.10.631 · Cited by 5
PULMONOLOGY: CFTR modulators for cystic fibrosis
Bertoncini, E., & Colomb-Lippa, D. (2013) · JAAPA · doi:10.1097/01720610-201302000-00013 · Cited by 5
Givinostat rescues folding of cystathionine beta-synthase and ameliorates murine homocystinuria
Petrosino, M., Zuhra, K., Mijatović, E., Philipp, T. M., Bremer, O., Ascenção, K., Szabó, C., & Majtán, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117079 · Cited by 4
Cystic fibrosis as a paradigmatic disease in bringing science to the bedside
Amaral, M. D., & Pankonien, I. (2025) · FEBS Letters · doi:10.1002/1873-3468.70101 · Cited by 4
Les enjeux de la médecine personnalisée appliquée à la mucoviscidose
Corvol, H., Taytard, J., Tabary, O., Rouzic, P. L., Guillot, L., & Clément, A. (2015) · Archives de Pédiatrie · doi:10.1016/j.arcped.2015.04.015 · Cited by 4
CFTR and Cystic Fibrosis
Farinha, C. M. (2017) · Springer briefs in molecular science · doi:10.1007/978-3-319-65494-2_1 · Cited by 5
Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review
Dobra, R., Edmondson, C. L., Hughes, D. A., Martín, I. R., & Davies, J. C. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0315-z · Cited by 4
Next‐generation preclinical models of lung development, physiology and disease
Jozani, K. A., Kouthouridis, S., Hirota, J. A., & Zhang, B. (2022) · The Canadian Journal of Chemical Engineering · doi:10.1002/cjce.24581 · Cited by 5
Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels
Campagna, N., Wall, E. M., Lee, K., Guo, J., Li, W., Yang, T., Baranchuk, A. M., El-Diasty, M. M., & Zhang, S. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000708 · Cited by 4
Exploring the “misfolding problem” by systematic discovery and analysis of functional-but-degraded proteins
Flagg, M. P., Lam, B., Lam, D. K., Le, T. M., Kao, A., Slaiwa, Y. I., & Hampton, R. Y. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-06-0248 · Cited by 5
Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies
Abinesh, R. S., Madhav, R., Sastri, K. T., Meghana, G. S., Akhila, A. R., & Balamuralidhara, V. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123186 · Cited by 4
Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy
Virant-Young, D., Thomas, J., Woiderski, S., Powers, M. L. E., Carlier, J., McCarty, J., Kupchick, T., & Larder, A. (2015) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2015.112 · Cited by 4
Fundamentals of Ion Transport Across Human Sweat Gland in Health and Disease
Reddy, M. M. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-55310-4_5 · Cited by 5
Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator
Al-Salmani, M., Sondo, E., Balut, C., Sheppard, D. N., Singh, A. K., & Pedemonte, N. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-55454-5_16 · Cited by 4
Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
Kashirskaya, N. Y., Petrova, N. V., & Зинченко, Р. А. (2021) · Вопросы современной педиатрии · doi:10.15690/vsp.v20i6s.2363 · Cited by 4
Use of Potentiators and Correctors to Rescue the Various Effects of Mutations in Cystic Fibrosis
(2018) · doi:10.29199/gene.101014 · Cited by 4
Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells
Huguet, F., Guellec, J., Kerbiriou, M., Gandy, M., Thomas, J., Férec, C., Benz, N., & Trouvé, P. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128866 · Cited by 4
Design of Crotoxin-Based Peptides with Potentiator Activity Targeting the ΔF508NBD1 Cystic Fibrosis Transmembrane Conductance Regulator
Ravatin, M., Odolczyk, N., Servel, N., Guijarro, J. I., Tagat, E., Chevalier, B., Baatallah, N., Corringer, P., Lukács, G. L., Edelman, A., et al. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167929 · Cited by 4
Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination
Pócsi, M., Fejes, Z., Bene, Z., Nagy, A. C., Balogh, I., Amaral, M. D., Maçek, M., & Nagy, B. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.04.001 · Cited by 4
Computational analysis of long-range allosteric communications in CFTR
Ayca, E., Altintel, B., Levanon, N. L., Ben‐Tal, N., Haliloǧlu, T., & Lewinson, O. (2023) · eLife · doi:10.7554/elife.88659 · Cited by 20
Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs
Lester, A., Sandman, M., Herring, C., Girard, C., Dixon, B., Ramsdell, H., Reber, C. P., Poulos, J., Mitchell, A., Spinney, A., et al. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00165 · Cited by 4
Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms
Murphy, M. P., & Caraher, E. M. (2016) · Drugs in R&D · doi:10.1007/s40268-015-0121-9 · Cited by 5
Transalpinecine and Analogues: First Total Synthesis, Stereochemical Revision and Biological Evaluation
Baudoin‐Dehoux, C., Castellan, T., Enel, M., André‐Barrès, C., Mirval, S., Becq, F., Ballereau, S., & Génisson, Y. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900071 · Cited by 4
Alpha1-Antitrypsin: Structure and Dynamics in Health, Disease and Drug Development
Jagger, A. M., Irving, J. A., Rashid, S. T., Lomas, D. A., & Gooptu, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803942-7.00005-2 · Cited by 4
Cystic Fibrosis
Rowe, S. M., Hoover, W., Solomon, G. M., & Sorscher, E. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00047-6 · Cited by 5
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis
Sinha, I. P., Southern, K. W., Dwan, K. M., & Patel, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010966 · Cited by 4
Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor
Delisle, B. P., & January, C. T. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx561 · Cited by 4
Highly Efficient Repair of the ΔF508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated EpitheliaPreprint
Vaidyanathan, S., Salahudeen, A. A., Sellers, Z. M., Bravo, D. T., Choi, S. S., Batish, A., Le, W., Sean de la, O., Kaushik, M. P., Galper, N., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/561183 · Cited by 4
Self-citation
Bibliometric analysis of chloride channel research (2004–2019)
Shi, J., Shi, S., Yuan, G., Jia, Q., Shi, S., Zhu, X., Zhou, Y., Chen, T., & Hu, Y. (2020) · Channels · doi:10.1080/19336950.2020.1835334 · Cited by 4
Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective
Losurdo, G., Gravina, A. G., Maroni, L., Gabrieletto, E. M., Ianiro, G., Ferrarese, A., Visintin, A., Frazzoni, L., Pellegatta, G., Sessa, A., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.008 · Cited by 4
Correction of a Traffic-Defective Missense ABCB11 Variant Responsible for Progressive Familial Intrahepatic Cholestasis Type 2
Lapalus, M., Mareux, E., Amzal, R., Drège, E., Riahi, Y., Petit, S., Banet, M., Falguières, T., Callebaut, I., Figadère, B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115232 · Cited by 4
Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator
Ambrosetti, A., Hagedorn, Z. J., Bono, T. R., Wen, H., Nguyen, R., Rodriguez-Cruz, K., Ali, J., Palacio, H., Phillips, A. J., Gilliland, S. D., et al. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00287.2024 · Cited by 3
Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis
S, M. S. V., Behl, S., Vaidya, P. C., Tiwari, P., Bharti, S. K., Nahan, N., Sahu, J. K., & Bansal, D. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103655 · Cited by 3
Pathogenic Pathways and Therapeutic Strategies in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Preval, K. M., Smith, A. O., & Pazour, G. J. (2025) · Journal of Cellular Signaling · doi:10.33696/signaling.6.144 · Cited by 4
Synthesis, characterization, and anticancer activity of organotin carboxylate containing aryl-substituted small rings
He, X., Liu, Z., Tang, Y., Yu, J., Tan, Y., & Jiang, W. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146465 · Cited by 3
Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
Berges, J., Graeber, S. Y., Hämmerling, S., Yu, Y., Krümpelmann, A., Stahl, M., Hirtz, S., Scheuermann, H., Mall, M. A., & Sommerburg, O. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1188051 · Cited by 3
Novel small molecule-mediated restoration of the surface expression and anion exchange activity of mutated pendrin causing Pendred syndrome and DFNB4
Jung, J., Noh, S. H., Jo, S., Song, D., Kang, M. J., Shin, M. H., Lee, H. J., Pyun, J., Namkung, W., Han, G., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115445 · Cited by 3
A Proximity Complementation Assay to Identify Small Molecules That Enhance the Traffic of ABCA4 Misfolding Variants
Piccolo, D., Zarouchlioti, C., Bellingham, J., Guarascio, R., Ziaka, K., Molday, R. S., & Cheetham, M. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084521 · Cited by 3
Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma
Thu, M., Qerqez, A. N., Hill, K. R., Azouz, L. R., Youngblood, H. A., Hill, S. E., Ku, Y., Peters, D. M. P., Maynard, J. A., & Lieberman, R. L. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae556 · Cited by 3
TTC7A missense variants in intestinal disease can be classified by molecular and cellular phenotypes
Jeshvaghani, Z. S., Mijnders, M., Muffels, I. J. J., van Beekhuizen, S., Kotlarz, D., Lindemans, C. A., Koletzko, S., Klein, C., Mokrý, M., Nieuwenhuis, E. E. S., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae185 · Cited by 3
Multi-modal Contrastive Learning with Negative Sampling Calibration for Phenotypic Drug Discovery
Rao, J., Lin, H., Chen, L., Xie, J., Zheng, S., & Yang, Y. (2025) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr52734.2025.02864 · Cited by 3
The Search for a Common Structural Moiety Among Selected Pharmacological Correctors of the Mutant Cftr Chloride Channel
Nieddu, E., Pollarolo, B., Mazzei, M. T., Anzaldi, M., Schenone, S., Pedemonte, N., Pesce, E., Galietta, L. J. V., & Mazzei, M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.118 · Cited by 3
Remarkable progress toward new treatments for cystic fibrosis
Eldredge, L. C., & Ramsey, B. W. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70272-3 · Cited by 3
Disease-Modifying Agents for the Treatment of Cystic Fibrosis
Tait, B. D., & Miller, J. P. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00020-1 · Cited by 3
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis
Hammond, J. A., & Connett, G. J. (2018) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2018.05.008 · Cited by 3
Is Phoenicia the Origin of the N1303K CFTR Mutation?
Farhat, R., Claude, P. M., Corbani, S., Mégarbané, A., Kitzis, A., & Ladevèze, V. (2019) · doi:10.23937/ijrdd-2017/1710006 · Cited by 3
Passaging Primary Human Bronchial Epithelia Reduces CFTR-Mediated Fluid Transport and Alters mRNA Expression
Wu, T., Wrennall, J. A., Dang, H., Baines, D. L., & Tarran, R. (2023) · Cells · doi:10.3390/cells12070997 · Cited by 3
Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants
Han, X., Li, D., Zhu, Y., & Schneider‐Futschik, E. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00362 · Cited by 3
Cystic fibrosis treatment: targeting the basic defect
Mondéjar-López, P., Pastor‐Vivero, M. D., Sánchez‐Solís, M., & Escribano, A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1280390 · Cited by 3
Stressors and Stress Responses in Cystic Fibrosis
Bebok, Z., & Fu, L. (2018) · Endoplasmic Reticulum Stress in Diseases · doi:10.1515/ersc-2018-0002 · Cited by 3
Combination therapy in Phe508del CFTR: how many will be enough?
Matos, A. M., & Matos, P. (2018) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2017/1.1113 · Cited by 3
Chronic Lung Pathologies That Require Repair and Regeneration
de Hilster, R. H. J., Li, M., Timens, W., Hylkema, M. N., & Burgess, J. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-29403-8_1 · Cited by 3
SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
Kumar, P., Soni, D. K., Sen, C., Larsen, M. B., Mazan-Mamczarz, K., Piao, Y., De, S., Gorospe, M., Frizzell, R. A., & Biswas, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96141-w · Cited by 3
Self-citation
The genome as pharmacopeia: Association of genetic dose with phenotypic response
Wadhawan, S., Runz, H., & Burchard, J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.02.005 · Cited by 3
Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25–28 March 2015
Verkman, A. S., Edelman, A., Amaral, M. D., Mall, M. A., Beekman, J. M., Meiners, T., Galietta, L. J. V., & Bear, C. E. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.10.001 · Cited by 3
Molecular Therapies for Cystic Fibrosis
Davies, G., Uta Griesenbach, D., Alton, E. W. F. W., & Davies, J. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00053-5 · Cited by 3
Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression
Peters, K. W., Gong, X., & Frizzell, R. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.695767 · Cited by 3
Self-citation
Why medicines work
Swinney, D. C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108175 · Cited by 3
Genomically-guided therapies: A new era for cystic fibrosis
Fajac, I., & Girodon, E. (2020) · Archives de Pédiatrie · doi:10.1016/s0929-693x(20)30050-6 · Cited by 3
Time for T...(T3, T4, rT3)? Focus on “Acute inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl− channel by thyroid hormones involves multiple mechanisms”
Fong, P. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00210.2013 · Cited by 3
Mucopurulent Triggering of the Airway Epithelium. Implications in Health and Cystic Fibrosis
Balázs, A., & Mall, M. A. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2554ed · Cited by 3
Elucidation of Global Trends in the Effects of VX-661 and VX-445 on the Expression of Clinical CFTR VariantsPreprint
McKee, A. G., McDonald, E. F., Penn, W. D., Kuntz, C. P., Noguera, K., Chamness, L. M., Roushar, F. J., Meiler, J., Oliver, K. E., Plate, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.14.512300 · Cited by 3
Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis
Barillaro, M., Avolio, J., Balachandran, S., Bartlett, C., Ip, W., Ouyang, H., Duan, W., Zabner, J., Keshavjee, S. H., Bear, C. E., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1651122 · Cited by 2
In vivo conformational space and defects of misfolded CFTR variants by covalent protein painting
Pankow, S., Bamberger, C., Martínez‐Bartolomé, S., Park, R., & Yates, J. R. (2025) · Nature Communications · doi:10.1038/s41467-025-63354-w · Cited by 4
Construction of Biaryl Skeletons Initiated with Benzyne Insertion into C═S Double Bond of Pyridine‐2(1 H )‐thiones
Long, L., Chen, L., Fu, H., Wu, L., Shi, J., & Li, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202519628 · Cited by 2
Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions
Borrelli, A., Venturini, A., Guidone, D., Santis, M. D., Montemitro, E., Alghisi, F., Ciciriello, F., & Galietta, L. J. V. (2025) · European Respiratory Journal · doi:10.1183/13993003.01171-2025 · Cited by 2
High-throughput screening identifies a trafficking corrector for long QT syndrome–associated KCNQ1 variants
Clowes, K. R., Vanoye, C. G., Chang-Gonzalez, A. C., Romaine, I. M., Stefanski, K. M., Wilkinson, M. C., Bauer, J. A., Hasaka, T. P., Days, E., Desai, R. R., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.201297 · Cited by 4
In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis
Metcalf, A., Hoppe, J. E., Martiniano, S. L., Zaretsky, M. V., Zemanick, E. T., & Sagel, S. D. (2026) · NeoReviews · doi:10.1542/neo.27-3-103 · Cited by 2
Treatment of Cystic Fibrosis
Filbrun, A. G., Lahiri, T., & Ren, C. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-32504-0_6 · Cited by 2
Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1
Barroso, M., Puchwein-Schwepcke, A., Buettner, L., Goebel, I., Küchler, K., Muntau, A. C., Delgado, A., García-Collazo, A. M., Martinell, M., Barril, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00292 · Cited by 2
Systematic deletion of symmetrical CFTR exons reveals new therapeutic targets for exon skipping antisense oligonucleotides
Peña‐Rasgado, C., Rodriguez-Manriquez, E., Dundr, M., Bridges, R. J., Hastings, M. L., & Michaels, W. E. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae017 · Cited by 2
Welsh, González, and Negulescu share Lasker Award recognizing transformative treatments for people with cystic fibrosis
Singer, B. D., & Budinger, G. R. S. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198727 · Cited by 2
Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant
Pastorino, C., Menta, L., Pesce, E., Lena, M., Tomati, V., Capurro, V., Duca, M. D., Terlizzi, V., Gramegna, A., Blasi, F., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330974 · Cited by 2
Modulating the cystic fibrosis transmembrane regulator and the development of new precision drugs
Froux, L., Billet, A., & Becq, F. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1547109 · Cited by 2
Cystic fibrosis: novel therapies, remaining challenges
Coulthard, K. P. (2018) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1516 · Cited by 2
Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.
Kirby, E. F., Heard, A., & Wang, X. (2013) · PubMed · Cited by 2
Therapy for Cystic Fibrosis Caused by Nonsense Mutations
Gambari, R., Breveglieri, G., Salvatori, F., Finotti, A., & Borgatti, M. (2015) · InTech eBooks · doi:10.5772/61053 · Cited by 2
Targeting the Root Cause of Cystic Fibrosis
Trescott, L., Holcomb, J., Spellmon, N., McLeod, C. M., Aljehane, L., Sun, F., Li, C., & Yang, Z. (2015) · Current Drug Targets · doi:10.2174/1389450115999141030144247 · Cited by 2
Combination lumacaftor and ivacaftor therapy for cystic fibrosis
McColley, S. A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1133282 · Cited by 2
Interaction non grata between CFTR's correctors and potentiators.
Lin, W.-Y., & Yu, Y. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.01.27 · Cited by 2
Exploring the Mechanisms Behind Cigarette Smoke-induced Internalization of CFTR
Marklew, A. J., Gilmore, R. C., Gray, M. A., & Tarran, R. (2014) · Newcastle University ePrints (Newcastle Univesity) · doi:10.25405/ncl.34237557 · Cited by 2
Personalization of therapies in rare diseases: a translational approach for the treatment of cystic fibrosis
Villella, V. R., Tosco, A., Esposito, S., Ferrari, E., Bona, G., Kroemer, G., Raia, V., & Maiuri, L. (2019) · Minerva Pediatrics · doi:10.23736/s0026-4946.19.05511-7 · Cited by 2
S-nitrosothiols signaling in cystic fibrosis airways
Liu, M., Zaman, R., Sawczak, V., Periasamy, A., Sun, F., & Zaman, K. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00223-w · Cited by 2
ABCC7/CFTR
Ford, R. C. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_13 · Cited by 2
Symposium Summaries
(2019) · Pediatric Pulmonology · doi:10.1002/ppul.22494 · Cited by 1
Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis
Vinhoven, L., Stanke, F., Hafkemeyer, S., & Nietert, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012351 · Cited by 2
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Targeted Therapeutics for Cystic Fibrosis
Veselu, D., Yeh, H., Rodrat, M., Bradbury, J. D., Fornies, Y. M., Li, H., Shoemark, D. K., Oliveira, A. S. F., Hwang, T., & Sheppard, D. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_8 · Cited by 2
Cystic Fibrosis: Does CFTR Malfunction Alter pH Regulation?
Douglas, B., & Mauri, E. (2013) · InTech eBooks · doi:10.5772/52342 · Cited by 2
Uses of Personalised Medicine in Current Pediatrics
Yousif, T. I., Bizanti, K., & Elnazir, B. (2016) · International Journal of Clinical Pediatrics · doi:10.14740/ijcp241w · Cited by 2
Targeting of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein with a Technetium‐99m Imaging Probe
Ferreira, V. F. C., Oliveira, B. L., Santos, J. D., Correia, J. D. G., Farinha, C. M., & Mendes, F. (2018) · ChemMedChem · doi:10.1002/cmdc.201800187 · Cited by 2
WITHDRAWN: Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain
Garić, D., Sanctis, J. B. D., Shah, J., Dumut, D. C., & Radzioch, D. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.100998 · Cited by 2
The Development and Characterization of VX-770 Molecular Probes
Hung, M. (2016) · TSpace (University of Toronto) · Cited by 2
Identification of in vivo CFTR conformations during biogenesis and upon misfolding by covalent protein painting (CPP)Preprint
Pankow, S., Bamberger, C., Martínez‐Bartolomé, S., Park, S. K., & Yates, J. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.433670 · Cited by 2
Medicinal Chemical Biology
Jones, L. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc256 · Cited by 2
Recent drug discovery success signals renaissance in biophysics
Connelly, P. R. (2022) · Biophysics Reviews · doi:10.1063/5.0099305 · Cited by 2
HERC3 E3 ligase provides an ERAD branch eliminating select membrane proteinsPreprint
Kamada, Y., Ohnishi, Y., Nakashima, C., Fujii, A., Terakawa, M., Hamano, I., Nakayamada, U., Katoh, S., Hirata, N., Tateishi, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.16.562477 · Cited by 2
Hit diffusion: limitations to drug discovery and structure-based design
Drie, J. H. V. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-021-00425-2 · Cited by 1

Authors: Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., & Negulescu, P. A.
Affiliations: Vertex Pharmaceuticals, San Diego, CA 92121;
Vertex Pharmaceuticals (United States) (US)
Stanford University (US)
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; and
Cystic Fibrosis Foundation (US)
Corresponding author: Negulescu, Paul A.
ORCID: Miller, Mark
Olson, Eric R.
Wine, Jeffrey J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2011-10-05
Volume: 108
Issue: 46
Pages: 18843-18848
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1105787108
PMC: PMC3219147
OpenAlex: W2071407356
Cited by: 1,088
References: 44
Citations by year: 2026: 24 · 2025: 48 · 2024: 48 · 2023: 57 · 2022: 64 · 2021: 83 · 2020: 98 · 2019: 95 · 2018: 101 · 2017: 103 · 2016: 77 · 2015: 85 · 2014: 84 · 2013: 61 · 2012: 58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Cystic Fibrosis Foundation Therapeutics
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords: cystic fibrosis, F508del-CFTR, CFTR correctors, lumacaftor, endoplasmic reticulum retention, chloride secretion, bronchial epithelial cells, CFTR mutations
MeSH terms: Aminopyridines, Bronchi, Cell Line, Cells, Cultured, Chemistry, Pharmaceutical, Chlorides, Cystic Fibrosis, Drug Evaluation, Preclinical, Epithelial Cells, Homozygote, Humans, Lung, Models, Genetic, Mutation, Drug Design, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks